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higher than self. Using DBDC questions seems to have additional benefit of refining
open ended questions. These results were higher especially in parametric estima-
tionmodels using only DBDC questions. This observation cautions us of selecting a
specific analytic method may influence the results. CONCLUSIONS: This study is
the first step toward resolution of controversies around economic evaluations of
healthcare in Korea and hopes to encourage more local research on this issue.
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PREVENTABLE HOSPITALIZATIONS AND HEALTH INSURANCE COVERAGE IN
HARRIS COUNTY, TEXAS
Murty S, Begley CE, Swint JM
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OBJECTIVES: Preventable hospitalizations (PHs) are hospitalizations that can be
avoided with appropriate and timely access to primary care. Lack of health insur-
ance has been associated with frequent PHs in several communities in the U.S. In
Harris County, public and private safety net clinics provide subsidized primary care
to uninsured individuals. Therefore, being uninsured may not result in unneces-
sary hospitalizations. The objective of this study was to determine the prevalence
of PHs and to examine the effect of health insurance on the risk of PHs in Harris
County (Houston), Texas.METHODS:This studywas restricted to non-elderly adult
(age 18 to 64) residents of Harris County, Texas. The Agency of Healthcare Research
and Quality (AHRQ) guidelines were used to identify a hospitalization as prevent-
able or not from the Texas Health Care Information Collection inpatient discharge
data – 2007. Prevalence wasmeasured as the rate of PHs; i.e. the number of PHs per
100 hospitalizations. Health insurance status was classified as “uninsured”, “Med-
icaid-insured” or “privately-insured”. A 2-analysis followed by a multivariable
logistic regression controlling for demographic and socioeconomic characteristics
was performed to determine the effect of health insurance on the risk of PHs.
RESULTS: There were 17,810 PHs among non-elderly adults in Harris County in
2007 (PH rate  7.83 PHs per 100 hospitalizations). Health insurance status was
significantly associated with PHs (2781.83; p0.001). In themultivariable model,
the uninsured had 60% higher odds of having a PH (OR1.628; p0.001) as com-
pared to the privately insured. Medicaid-insurance was also associated with a
marginally higher risk of PHs (OR1.065; p0.05). CONCLUSIONS: Lack of health
insurance is an important factor in determining risk of PHs in Harris County, de-
spite the presence of safety net clinics. If recent healthcare reforms are successful
in increasing health insurance coverage, a large proportion of these unnecessary
hospitalizations may be avoided.
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OBJECTIVES: To assess impact of the Medicare Part D coverage gap on prescription
drug utilization andmedication adherence using data fromMedicare beneficiaries
enrolled in a large health plan in New Mexico in 2007. METHODS: Quasi-experi-
mental, retrospective, pre-post with control group study design was utilized. Pre-
and post-coverage gap prescription drug utilization and medication adherence of
beneficiaries enrolled in a health plan with no prescription drug coverage during
the coverage gap (no coverage plan) was compared with generic drug coverage
(generic coverage plan) and full prescription drug coverage (full coverage plan) plan
beneficiaries. Prescription drug utilization was assessed using total number of pre-
scriptions per member. Medication adherence was measured using Medication
Possession Ratio and the Proportion of Days Covered (PDC). Difference-in differ-
ence analysis (DiD) was used to compare pre- and post-coverage gap prescrip-
tion drug utilization and medication adherence between the three plans.
RESULTS: Of the 14,846 beneficiaries who met inclusion and exclusion criteria,
2,661 (17.92%) entered the coverage gap in 2007. DiD analyses indicated that
beneficiaries in the no coverage plan filled significantly fewer prescriptions in
the post-coverage gap period, than beneficiaries in the full (14.67 fewer prescrip-
tions; p0.001) and generic (12.52 fewer prescriptions; p0.001) coverage plans.
Significant decrease in post-coverage gap medication adherence was observed
between no coverage and full coverage plan beneficiaries with respect to statins
(5.8%), ARBs (16%) and PPIs (18.1%). Significant decrease in post-coverage gap
medication adherence was observed between no coverage and generic coverage
plan beneficiaries utilizing statins (1.1%) and ARB’s (12%). No significant differ-
ences were observed between full and generic coverage plan beneficiaries. Sig-
nificant differences in adherence were found only when adherence was mea-
sured using the PDC. CONCLUSIONS: Lack of prescription drug coverage during
the Medicare Part D coverage gap may lead to decreased utilization and adher-
ence to certain classes of prescription drugs.
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OBJECTIVES: The aim of the study was to evaluate the quality of pharmacoeco-
nomic studies based in India.METHODS: A literature search was conducted using
PubMed, Medline, EconLit, PsycInfo and Google Scholar to identify published work
on pharmacoeconomics studies based in India. Original research studies that eval-
uated pharmaceuticals, and were conducted between 1990 and 2010 in India were
included. Two reviewers independently reviewed the articles using a subjective
10-point scale (10 being the highest) and the 100-point ‘Quality of Health Economic
Studies’ (QHES) questionnaire (100 being the highest). RESULTS: The included ar-
ticles (n29) were published in 23 different journals. Only 9 articles were published
in journals based in India. The first article was published in 1998. Each article was
written by an average of five authors. Themajority of authors resided in India (62%)
at the time of publication and had a medical background (90%). Cost-effectiveness
analysis was the most frequently used method of analysis (79%). The source of
funding and study perspective was not listed in 45% and 41% of the studies respec-
tively. The study design was a randomized controlled trial for 41% of the studies.
The mean subjective quality score of all the articles (n  29) was 7.8 (SD1.3) and
the mean QHES scores for the studies evaluating costs and outcomes (n  24) was
86 (SD6). The quality score was significantly (p0.05) related to country of resi-
dence of primary author (non-Indiahigher) and the study design (randomized
controlled trialshigher). CONCLUSIONS: The need for economic evaluation of
pharmaceuticals is imperative, especially in developing countries like India; be-
cause it can help decisionmakers allocate scarce resources in a justifiablemanner.
Standardization of guidelines, and improved pharmacoeconomic education -start-
ing from the undergraduate level to specialization - are two suggestions to help to
improve the quality of the pharmacoeconomic research in India.
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Puig-Peiró R, Towse A, Mestre-Ferrandiz J
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OBJECTIVES: To understand the extent of likely variation if any in underlying
relative efficacy and relative effectiveness of drugs used in one or more of the 27
Member States (MS). METHODS: A systematic literature review of studies in four
databases was conducted for the period January 2000 - May 2010: Medline, Embase,
EconLit and Health Management Information Consortium (HMIC). Logical combi-
nations of keywords related to effectiveness, generalisability, external validity,
transferability, Europe and review were searched. RESULTS: A total of 326 articles
were initially identified and ten formed the bases of the review. Nine were
reviews or original cost-effectiveness studies and relevant data on the effective-
ness results was extracted. First, we found that there is a common assumption
in the literature that relative efficacy is constant across countries and therefore
generalisable. Less is known about whether relative effectiveness is indeed
similar or different. Second, we grouped the factors that could potentially in-
troduce variation in relative effectiveness: (i) patients and disease characteris-
tics; (ii) comparators used; (iii) different measures of health outcomes; (iv) vari-
ations in clinical practice. Third, no observational studies were identified.
Evidence from studies using efficacy data, mainly from RCTs, was mixed; three
studies found no differences in clinical outcomes across countries, one study
found differences due to patients’ characteristics and severity and another
study using multilevel analysis found country and patients characteristics ex-
plaining partly the heterogeneity of treatment effects. One review report differ-
ences in clinical practice as one major causes of variations in clinical outcomes
between countries. CONCLUSIONS: The literature was scarce and therefore
more evidence is needed before any statement can be claimed on the existence
of variations in relative effectiveness or efficacy in different countries. Future
collaboration among the MS harmonising methodology, generating data and
sharing patients’ registry data will be crucial to produce this evidence.
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OBJECTIVES: Evidence has recently emerged regarding the presence of investigator
learning curves in the context of clinical trials (i.e., the association between clinical
protocol departures and patient enrollment sequence). We reviewed the literature
to identify factors contributing to clinical trial learning curves and potential im-
pacts of learning curves on outcomes accuracy, patient safety and overall trial
success. METHODS: The PubMed database was searched for studies describing
clinical trial learning curve effects and potential solutions to these effects, using
search term combinations including “clinical trial”, “clinical protocol”, “learning
curve”, and “enrollment sequence”. RESULTS: Learning curve effects were identi-
fied in trials including those for treatment of sepsis (PROWESS and ADDRESS) and
high-risk cardiac disease (VALIANT). Outcomes of these trials potentially resulting
from learning curves included ambiguous treatment benefit, increased adverse
events andmortality, and overall trial failure. Potential contributing factors include
those related to study site (e.g., large multicenter trials; sites with poor enrollment
or previous trial experience; inexperienced staff and high staff turnover), study
protocols (e.g., imprecise or complex protocols), and disease severity. Preventing
such learning curve effects would likely have required extensive trial site and staff
screening and training, as well as improved trial protocol design prior to first pa-
tient enrollment. Clinical trial simulation, a methodology identified in several re-
ports, could potentially address clinical trial learning curves by improving protocol
design and staff competence. This approach, which focuses on human factors
involved in conducting clinical protocols, offers the potential to improve the accu-
racy of measured trial outcomes and decrease the likelihood of premature trial
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termination. CONCLUSIONS: Clinical trial learning curves have significant impli-
cations for outcomes research accuracy, patient safety, and overall trial success.
Clinical trial simulation may provide a broadly applicable methodology for ad-
dressing several factors associated with clinical trial learning curve effects and for
improving the accuracy of clinical trial outcomes.
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OBJECTIVES: Recent developments in the United States (US) health care reform
and funding for comparative effectiveness research suggest that use of electronic
medical records (EMR) in outcomes research may increase over time. EMR can be
particularly useful when outcomes are not well-defined with diagnosis or proce-
dures codes or when clinical data are needed. The objective of this study was to
review trends in the use of EMR during the past decade. METHODS: A review of
published literature was conducted in PubMed for years 2001 through 2010 to iden-
tify outcomes studies in the US that used EMR. Internal quality assurance studies
and validation studies that used EMR were excluded. The number of studies, set-
ting of care, patient population,whether the studywas comparative, and anynoted
limitationswere examined. RESULTS:A total of 58 EMR-based, outcomes studies in
the USwere identified over the past decade; increasing from 3 in 2001 to 12 in 2010.
The majority of studies included outpatient EMR. Studies included a variety of
patient populations with over one-third in cardiovascular disease, psychiatric dis-
ease, and diabetes combined. The percent of studies that were comparative ranged
from 0% in 2001 to 45% in 2010. Measures of effectiveness varied widely and in-
cluded lab values, clinical measures, and health-related quality-of-life outcomes.
Some noted limitations on the use of EMR data in outcomes research included lack
of representativeness of all care delivered across practice settings, lack of general-
izability and standardization, and reliance on health care provider reporting.
CONCLUSIONS: Although the use of EMR in outcomes research has increased
slowly in the past decade, the proportion of comparative studies using EMR has
increased over time. As the industry works to standardize EMR andmore advanced
outcomes are collected in EMR systems, EMR data may play a larger role in com-
parative effectiveness research.
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RESEARCH: AN APPLICATION OF THE PRECIS FRAMEWORK
Vincent L
Quintiles Global Consulting, Hawthorne, NY, USA
OBJECTIVES: In recent years, comparative effectiveness research (CER) has gained
increasing interest and investment across major life science and health policy
stakeholder groups: regulators, biopharmaceuticals, physicians, patients, and pay-
ers. Onemethod, large simple trial (LST), a hybrid of observational cohort study and
randomized control trial (RCT), is designed for large numbers of patients in post-
approval research and is a choice study design for comparing the relative strengths
and weaknesses of medical interventions. The objective of this study was to eval-
uate the current landscape of LSTs to capture key themes in the future outlook of
CER. METHODS: A structured abstract review and funnel analysis was conducted
using data available through ClinicalTrials.gov. Using the search terms, “phase IV”,
“post-marketing”, “randomized”, and “multi-centered”, 2230 clinical trials were
filtered with restricted parameters for number of patients (n1000), evidence of
blinding, stated objective of comparative effectiveness, and date of trial initiation.
RESULTS: To gain a perspective on current and future outlook, only trials initiated
between 2009 and 2010 (n10) were assessed in this phase of study. Using the
Pragmatic Explanatory Continuum Indicator Summary (PRECIS) framework origi-
nally developed for pragmatic trials, the analysis revealed an important theme.
When applying key domain criteria – practitioner expertise, treatment flexibility,
eligibility criteria, health outcomes, study duration, intent-to-treat (ITT), and pri-
mary outcome analysis, as defined by the PRECIS framework – less than 50% of the
LST CER trials were designed to measure effectiveness, as opposed to efficacy.
CONCLUSIONS: According to findings, there has been an uptake on the use of LSTs
in investigating the relative effectiveness of interventions. However, considering
the increase in governmental pressure to reduce healthcare spending by improving
quality of treatment; it is important that these LSTs are conducted to truly capture
effectiveness. For that reason, there is need for further research to extract and
develop new frameworks for evaluation.
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OBJECTIVES: To investigate the state of health economic research in Russia avail-
able in the English language by describing the number and characteristics of the
articles, and assessing the quality of these articles.METHODS: The study assessed
the state of health economics and pharmacoeconomics research in Russia. We
conducted a literature search to identify health economics articles pertaining to
Russia. Each article in the final sample was scored by two reviewers independently
using the data-collection form designed for the study. RESULTS: In total, 16 studies
investigating a wide variety of diseases were included in the study. These articles
were published in 15 different journals all based outside of Russia between 1994
and 2009. On average, each article was written by seven authors. Most first authors
had medical/clinical training and resided in the USA (n  8) at the time of publica-
tion of the study. Based on a scale of 1–10,with 10 indicating the highest quality, the
mean quality score for all studies was 8.09 (SD  1.29) and 25% of the articles were
of fair quality (score 5–7). The quality of articles was statistically significantly re-
lated (P  0.05) to the primary health intervention (pharmaceuticals  non-phar-
maceuticals) and primary training of the first author (medical  non-medical).
CONCLUSIONS: The conduct of health economics and pharmacoeconomics research
in Russia in the English language is limited and, on average, the published articles
were of good quality. However, about one-quarter of published articles were of fair
quality. More health economics research in English is warranted in Russia.
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OBJECTIVES: This study compares the patient characteristics, insurance coverage,
disease prevalence, and utilization patterns of inpatient and emergency depart-
ment (ED) services between homeless and non-homeless people using a new data
source that has not been employed in existing studies.METHODS: A retrospective
data analysis was conducted to compare differences in patient characteristics,
insurance coverage, disease prevalence, and utilization patterns between home-
less and non-homeless individuals who visited a hospital or hospital-based emer-
gency department. For each service type, separate rates were created for homeless
and non-homeless populations and then compared. The Healthcare Cost and Uti-
lization Project (HCUP) State Inpatient Databases (SID) and State Emergency De-
partmentDatabases (SEDD) for 2008were used in the analysis. The SID employed in
this study include 15.9 million inpatient hospital discharges from community hos-
pitals in ten states – Arizona, California, Colorado, Florida, Georgia, Massachusetts,
Missouri, NewYork, Pennsylvania andWisconsin. 177,056 of these dischargeswere
homeless patients. The SEDD employed in this study include 23.7 million visits to
ED, where patients were treated and released, from seven states (i.e., Arizona,
Florida, Georgia, Massachusetts, Missouri, New York and Wisconsin). 49,595 of
these visits were homeless patients. RESULTS: The uninsured homeless (non-
homeless) patients were accountable for 28.1% (4.6%) of inpatient admissions and
42.85 (21%) of ED visits. Medicaid covered 48.2% of all inpatient discharges and
34.7% of all ED visits by homeless patients. 73.7% (50.6%) of homeless (non-home-
less) inpatient admissions came through EDs. Homeless patients with mental dis-
orders accounted for 22.4% of all homeless inpatient discharges and 49% of all
homeless ED visits. A majority of the mental disorder diagnosis in both settings of
care were alcohol-related disorders, mood disorders, and schizophrenia.
CONCLUSIONS: The profile of homeless and non-homeless patients differed sig-
nificantly by insurance status and by race in both the inpatient and emergency
department settings.
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OBJECTIVES: Health economies outside Western Europe are increasingly adopting
evidence-based decision-making, but implementation methods differ. Common-
alities in the approach taken in Turkey and Poland nevertheless illustrate the role
of a previously developed reimbursement process in the adoption of HTA. Insights
from this comparisonmay have implications for industry, government and private
reimbursement authorities worldwide. METHODS: Turkey and Poland were se-
lected for comparison due to their relatively recent adoption of HTA within an
established reimbursement system. A total of 18 stakeholderswere interviewed via
telephone interviews to understand current and future utilisation of HTA in reim-
bursement. The study evaluated the impact of the following decision-making do-
mains: clinical differentiation, prioritisation of unmet needs, price, and presenta-
tion requirements (e.g. budget impact analysis). A comparisonwas thenmade on a
rating scale devised to account for these influencing factors. RESULTS: In Turkey
the pharmacoeconomics unit of the Social Security Institute is responsible for
economic evaluation. However the Polish HTA body AHTAPol is more directly in-
volved in the HTA process. All 9 Polish respondents scored high on the influence of
HTA in access decisions while just 2 respondents in Turkey considered HTA to be
extremely influential in reimbursement. However, pricing decisions in both coun-
tries are based on international referencing to varying degrees. CONCLUSIONS:
Despite superficial similarities in the structure of their reimbursement systems,
HTA in Poland is more closely integrated with decision making than in Turkey. At
present HTA plays a formal role in the Turkish system but a negotiation-based
approach remains to customary channel for value arguments. However, the rapid
pace of change in the Turkish reimbursement system suggests the need for further
ongoing research.
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RELATIONSHIP OF HERBAL KNOWLEDGE TOWARDS ATTITUDE FORMATION
AMONG FUTURE PHARMACISTS
Sura SD, Chabria A, Sansgiry S
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OBJECTIVES: Trends in the use of herbalmedications continue to rise. Pharmacists
have an opportunity to provide consumers with evidence based information. This
study examined pharmacy student’s knowledge regarding herbal medication from
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